Fig. 4.

Median fold change in plasma cytokines and chemokines following administration of Nexvax2. Assessments were made during the escalation phase, at 150 μg of Nexvax2 (previously defined maximum tolerated dose), and after the first, second, forth, and eighth administrations at the 300 μg and 900 μg maintenance doses. Plasma cytokines and chemokines were measured pre-treatment, and at 4, 6, and 10 h post-treatment.